ULBP2 Lentivirus

Catalog #

78744

$850 *

Size: 500 µl x 2

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

The ULBP2 (UL16 binding protein 2) Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce most types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with human ULBP2 (NM_025217.4) driven by an EF1a promoter. The lentiviruses also transduce a puromycin selection gene (Figure 1).

Figure 1: Schematic of the lenti-vector used to generate the ULBP2 Lentivirus.

●

Synonyms

UL16 Binding Protein 2, Retinoic Acid Early Transcript 1H, NKG2D Ligand 2, and ALCAN-Alpha

●

Product Data Gallery

Expression of human ULBP2 in HEK293 cells transduced with ULBP2 lentiviruses

Product Info

Storage and Usage

Citations

Supplied As

Two vials (500 µl x 2) of lentivirus at a titer ≥10⁷ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

Formulation

The lentiviruses were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Background

ULBP2 (UL16 binding protein 2) is a glycoprotein related to MHC class I molecules that belongs to the family of unique length 16 (UL16) binding proteins. It is a stress-induced ligand for the activating NKG2D receptor in NK (natural killer) cells. It contains the MHC class-I-like α1-α2 domains but lacks the α3 region present in MICA/B proteins and uses GPI (glycosylphosphatidylinositol) as anchor to the plasma membrane. Stress ligands respond to viral infections, heat shock, or other cellular stresses, and are also crucial in immune surveillance. ULBP2 is expressed at low levels in normal tissues but overexpressed in several types of cancer (such as liver, breast, cervical and skin), with its levels correlated to the severity of the prognosis. Targeting ULBP2, for example with miR-6071, reduced tumorigenicity in glioblastoma. Targeting ULBP2 may prove beneficial in combination with NK-based cancer therapy.

Storage/Stability

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.

Applications

Expression of human ULBP2 in cells of interest.
Generate stable cell lines expressing human ULBP2 (puromycin resistant).

Shipping Temperature

-80°C

Notes

To generate ULBP2-expressing stable cells, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve), for selection of the transduced cells. Visit: https://bpsbioscience.com/cell-line-faq for guidelines on how to perform a kill curve.

Biosafety
The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Troubleshooting Guide
Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For further questions, email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

ULBP2 Lentivirus

PRODUCTS

SERVICES

RESOURCES

COMPANY